Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for c…
This bill amends section 1192(e)(1)(A)(ii) of the Social Security Act to change the statutory negotiation period for small‑molecule drugs under the Drug Price Negotiation Program from 7 years to 11 years, aligning it with the period applicable to biologic candidates. The change is effective as if included in the enactment of Public Law 117–169 (the Inflation Reduction Act).
Progressives stress delayed affordability and patient cost harms
Narrow technical change could move quickly, but affects high-profile drug pricing mechanics and may attract opposition.
This bill amends section 1192(e)(1)(A)(ii) of the Social Security Act to change the statutory negotiation period for small‑molecule drugs under the Drug Price Negotiation Program from 7 years to 11 years, aligning it with the period applicable to biologic candidates.
The change is effective as if included in the enactment of Public Law 117–169 (the Inflation Reduction Act).
Technically small but alters a high-profile program and benefits industry stakeholders, raising political friction despite limited text.
How solid the drafting looks.
Progressives stress delayed affordability and patient cost harms
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives stress delayed affordability and patient cost harms
Likely to view the bill negatively because it delays when small‑molecule drugs enter government price negotiations, potentially keeping prices higher for more years.
They will note the change favors manufacturers and undermines the Drug Price Negotiation Program’s intent to lower prescription drug costs for consumers.
A centrist would see a neutral-to-skeptical view: the bill equalizes treatment between drug types, which is a principled fix, but it also delays negotiation timing which could raise near‑term costs.
They would weigh fairness to manufacturers against potential impacts on patients and federal spending.
A conservative is likely to view the bill favorably because it delays government price negotiation for small‑molecule drugs, preserving market exclusivity and reducing near‑term regulatory pressure on industry.
They will emphasize protecting innovation incentives and rolling back aggressive price controls.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Technically small but alters a high-profile program and benefits industry stakeholders, raising political friction despite limited text.
The bill has not accumulated any surfaced votes yet.
Progressives stress delayed affordability and patient cost harms
Technically small but alters a high-profile program and benefits industry stakeholders, raising political friction despite limited text.
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for To amend title XI of the Social Security Act to equalize the n…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.